190 related articles for article (PubMed ID: 21453263)
1. Enhancement of solubility and permeability of Candesartan cilexetil by using different pharmaceutical interventions.
Shaikh SM; Avachat AM
Curr Drug Deliv; 2011 Jul; 8(4):346-53. PubMed ID: 21453263
[TBL] [Abstract][Full Text] [Related]
2. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
[TBL] [Abstract][Full Text] [Related]
3. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
Jain S; Reddy VA; Arora S; Patel K
Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
[TBL] [Abstract][Full Text] [Related]
4. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.
Nekkanti V; Pillai R; Venkateshwarlu V; Harisudhan T
Pharm Dev Technol; 2009; 14(3):290-8. PubMed ID: 19235553
[TBL] [Abstract][Full Text] [Related]
5. Solid dispersion systems for enhanced dissolution of poorly water-soluble candesartan cilexetil: In vitro evaluation and simulated pharmacokinetics studies.
Ali ISM; Sajad UA; Abdul Rasool BK
PLoS One; 2024; 19(6):e0303900. PubMed ID: 38843120
[TBL] [Abstract][Full Text] [Related]
6. New supersaturating drug delivery system as strategy to improve apparent solubility of candesartan cilexetil in biorelevant medium.
Pinto JMO; Leão AF; Alves GF; Mendes C; França MT; Fernandes D; Stulzer HK
Pharm Dev Technol; 2020 Jan; 25(1):89-99. PubMed ID: 31583925
[TBL] [Abstract][Full Text] [Related]
7. Melt dispersion granules: formulation and evaluation to improve oral delivery of poorly soluble drugs - a case study with valsartan.
Chella N; Tadikonda R
Drug Dev Ind Pharm; 2015 Jun; 41(6):888-97. PubMed ID: 24796274
[TBL] [Abstract][Full Text] [Related]
8. Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation.
Surampalli G; Nanjwade BK; Patil PA; Chilla R
Drug Deliv; 2016 Sep; 23(7):2124-2138. PubMed ID: 25080228
[TBL] [Abstract][Full Text] [Related]
9. Preparation, characterization and
Amer AM; Allam AN; Abdallah OY
Drug Dev Ind Pharm; 2019 Jul; 45(7):1140-1148. PubMed ID: 30912678
[TBL] [Abstract][Full Text] [Related]
10. Solid self-microemulsifying formulation for candesartan cilexetil.
Nekkanti V; Karatgi P; Prabhu R; Pillai R
AAPS PharmSciTech; 2010 Mar; 11(1):9-17. PubMed ID: 20013081
[TBL] [Abstract][Full Text] [Related]
11. Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique.
Marasini N; Tran TH; Poudel BK; Cho HJ; Choi YK; Chi SC; Choi HG; Yong CS; Kim JO
Int J Pharm; 2013 Jan; 441(1-2):424-32. PubMed ID: 23174408
[TBL] [Abstract][Full Text] [Related]
12. DEVELOPMENT OF SOLID LIPID NANOCARRIERS FOR ORAL DELIVERY OF CANDESERTAN CILEXETIL.
Ugurlu T; Nalbantoglu A; Sengel-Turk CT
Acta Pol Pharm; 2016 Nov; 73(6):1631-1638. PubMed ID: 29634119
[TBL] [Abstract][Full Text] [Related]
13. Hydroxypropyl-β-cyclodextrin functionalized calcium carbonate microparticles as a potential carrier for enhancing oral delivery of water-insoluble drugs.
Zhang L; Zhu W; Lin Q; Han J; Jiang L; Zhang Y
Int J Nanomedicine; 2015; 10():3291-302. PubMed ID: 25995635
[TBL] [Abstract][Full Text] [Related]
14. Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation.
Paudel A; Ameeduzzafar ; Imam SS; Fazil M; Khan S; Hafeez A; Ahmad FJ; Ali A
Curr Drug Deliv; 2017; 14(7):1005-1015. PubMed ID: 28034361
[TBL] [Abstract][Full Text] [Related]
15. Three dimensional macroporous hydroxyapatite/chitosan foam-supported polymer micelles for enhanced oral delivery of poorly soluble drugs.
Zhang Y; Dong K; Wang F; Wang H; Wang J; Jiang Z; Diao S
Colloids Surf B Biointerfaces; 2018 Oct; 170():497-504. PubMed ID: 29960950
[TBL] [Abstract][Full Text] [Related]
16. The effect of polysorbate 20 on solubility and stability of candesartan cilexetil in dissolution media.
Hoppe K; Sznitowska M
AAPS PharmSciTech; 2014 Oct; 15(5):1116-25. PubMed ID: 24871550
[TBL] [Abstract][Full Text] [Related]
17. Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug.
Aly UF; Sarhan HA; Ali TFS; Sharkawy HAE
Drug Des Devel Ther; 2020; 14():1851-1865. PubMed ID: 32523332
[TBL] [Abstract][Full Text] [Related]
18. Host-Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism.
Ntountaniotis D; Andreadelis I; Kellici TF; Karageorgos V; Leonis G; Christodoulou E; Kiriakidi S; Becker-Baldus J; Stylos EK; Chatziathanasiadou MV; Chatzigiannis CM; Damalas DE; Aksoydan B; Javornik U; Valsami G; Glaubitz C; Durdagi S; Thomaidis NS; Kolocouris A; Plavec J; Tzakos AG; Liapakis G; Mavromoustakos T
Mol Pharm; 2019 Mar; 16(3):1255-1271. PubMed ID: 30681344
[TBL] [Abstract][Full Text] [Related]
19. Corroboration of naringin effects on the intestinal absorption and pharmacokinetic behavior of candesartan cilexetil solid dispersions using in-situ rat models.
Surampalli G; K Nanjwade B; Patil PA
Drug Dev Ind Pharm; 2015; 41(7):1057-65. PubMed ID: 24918161
[TBL] [Abstract][Full Text] [Related]
20. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes.
Yan YD; Sung JH; Kim KK; Kim DW; Kim JO; Lee BJ; Yong CS; Choi HG
Int J Pharm; 2012 Jan; 422(1-2):202-10. PubMed ID: 22085435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]